← back to search

Paulo J.C. Lin

Acuitas Therapeutics (Canada) · CA
Area of research
Molecular Biology · Infectious Diseases
Research interest
Research interests include RNA Interference and Gene Delivery, SARS-CoV-2 and COVID-19 Research, Immunotherapy and Immune Responses, and Animal Virus Infections Studies.
h-index
37
citations
6,773
works
97
NIH funding
primary concept
email

Recent publications

Computationally designed mRNA-launched protein nanoparticle immunogens elicit protective antibody and T cell responses in mice
Science Translational Medicine 2025cited by 12position: middledoi
mRNA delivery of mosaic-8 pan-sarbecovirus RBD vaccines elicits distinct antibody epitope signatures
bioRxiv (Cold Spring Harbor Laboratory) 2025cited by 1position: middledoi
Exploring Mechanisms of Lipid Nanoparticle‐Mucus Interactions in Healthy and Cystic Fibrosis Conditions
Advanced Healthcare Materials 2024cited by 33position: middledoi
Molecular fate-mapping of serum antibody responses to repeat immunization
Nature 2023cited by 178position: middledoi
A universal influenza mRNA vaccine candidate boosts T cell responses and reduces zoonotic influenza virus disease in ferrets
Science Advances 2022cited by 63position: middledoi
A minimally-edited mouse model for infection with multiple SARS-CoV-2 strains
Frontiers in Immunology 2022cited by 9position: middledoi
A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta
bioRxiv (Cold Spring Harbor Laboratory) 2022cited by 3position: middledoi
Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses
Immunity 2021cited by 703position: middledoi
A Single Immunization with Nucleoside-Modified mRNA Vaccines Elicits Strong Cellular and Humoral Immune Responses against SARS-CoV-2 in Mice
Immunity 2020cited by 387position: middledoi
Contributors
Elsevier eBooks 2019cited by 0position: middledoi
Influence of Polyethylene Glycol Lipid Desorption Rates on Pharmacokinetics and Pharmacodynamics of siRNA Lipid Nanoparticles
Molecular Therapy — Nucleic Acids 2013cited by 474position: middledoi
Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA
Molecular Therapy — Nucleic Acids 2012cited by 658position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Ying K. Tam · Acuitas Therapeutics (Canada)5 papers (2012–2024)Pieter R. Cullis · University of British Columbia3 papers (2012–2024)Norbert Pardi · University of Pennsylvania3 papers (2022–2023)Hiromi Muramatsu · University of Pennsylvania3 papers (2022–2023)Luka Mesin · Rockefeller University2 papers (2022–2023)Sam Chen · University of Illinois Urbana-Champaign2 papers (2012–2013)Gabriel D. Victora · Rockefeller University2 papers (2022–2023)Vivian Tat · The University of Texas Medical Branch at Galveston1 papers (2022–2022)Panatda Saenkham-Huntsinger · Texas A&M University1 papers (2022–2022)Paul D. Bieniasz · Rockefeller University1 papers (2023–2023)Brandon Carter · Massachusetts Institute of Technology1 papers (2022–2022)Sandra Nakandakari-Higa · Howard Hughes Medical Institute1 papers (2022–2022)Caroline Vilas Boas de Melo · National Institute for Public Health and the Environment1 papers (2022–2022) · 1 papers (2013–2013)Sarah Hedtrich · University of British Columbia Hospital1 papers (2024–2024) · 1 papers (2024–2024)Clarety Kaseke · Ragon Institute of MGH, MIT and Harvard1 papers (2022–2022)Florence Peters · Utrecht University1 papers (2022–2022)Juliana Bortolatto · Howard Hughes Medical Institute1 papers (2022–2022)Angelina M. Bilate · Rockefeller University1 papers (2022–2022)